56 citations,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.
[object Object] 21 citations,
January 2016 in “Skin appendage disorders” Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.
5 citations,
February 2014 in “PubMed” Hair loss in Telogen effluvium is often chronic, linked to stress, and lacks a confirmed treatment, but topical corticosteroids may be used.
1 citations,
August 2021 in “Internal Medicine Journal” After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.
70 citations,
February 2015 in “Expert Opinion on Drug Discovery” Topical drugs and near-infrared light therapy show potential for treating alopecia.